Callan Family Office LLC Decreases Stock Holdings in Amgen Inc. $AMGN

Callan Family Office LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 4.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,795 shares of the medical research company’s stock after selling 1,557 shares during the quarter. Callan Family Office LLC’s holdings in Amgen were worth $11,514,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Keebeck Wealth Management grew its position in shares of Amgen by 4.0% in the 2nd quarter. Keebeck Wealth Management now owns 2,529 shares of the medical research company’s stock worth $916,000 after buying an additional 98 shares during the last quarter. Blue Capital Inc. bought a new position in shares of Amgen in the 2nd quarter worth about $240,000. Keating Financial Advisory Services Inc. increased its stake in shares of Amgen by 7.0% during the second quarter. Keating Financial Advisory Services Inc. now owns 1,289 shares of the medical research company’s stock valued at $467,000 after purchasing an additional 84 shares in the last quarter. OneAscent Family Office LLC increased its position in Amgen by 37.6% during the 2nd quarter. OneAscent Family Office LLC now owns 874 shares of the medical research company’s stock valued at $317,000 after buying an additional 239 shares in the last quarter. Finally, Impax Asset Management Group plc increased its holdings in shares of Amgen by 4.6% during the second quarter. Impax Asset Management Group plc now owns 18,289 shares of the medical research company’s stock valued at $6,623,000 after acquiring an additional 796 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

AMGN stock opened at $439.33 on Friday. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $443.20. The company has a fifty day simple moving average of $379.03 and a two-hundred day simple moving average of $361.95. The firm has a market capitalization of $237.51 billion, a P/E ratio of 27.30, a price-to-earnings-growth ratio of 3.13 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same period in the previous year, the firm earned $6.02 earnings per share. Amgen’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Analysts anticipate that Amgen Inc. will post 22.92 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be issued a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. Amgen’s payout ratio is presently 62.65%.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Solid operating performance and dividend support the valuation. Amgen’s second-quarter results exceeded expectations, with revenue rising year over year and earnings per share topping consensus. Continued growth and the company’s dividend are helping support investor confidence. Amgen stock holds close to record high as Q2 2026 growth and dividend support valuation
• Positive Sentiment: Analysts raised their outlook. Argus increased its price target to $460 from $375 while maintaining a Buy rating, citing the latest quarterly performance and progress across Amgen’s drug portfolio. Separate reports also highlighted favorable forecasts from Mizuho and Cantor Fitzgerald, reinforcing the bullish analyst sentiment. Amgen gets a fresh target
• Positive Sentiment: Tarlatamab development advanced. Amgen’s Phase 3 DeLLphi-315 study is evaluating a subcutaneous injection of tarlatamab against the current intravenous infusion approach in lung cancer. A successful shot formulation could improve convenience and broaden the commercial potential of the drug. Amgen advances tarlatamab shot versus infusion in Phase 3 lung cancer study
• Positive Sentiment: Trading momentum and options activity were unusually strong. Amgen was identified as a momentum stock after a substantial recent share-price rally, while call-option volume surged well above typical levels, suggesting increased bullish positioning.
• Neutral Sentiment: Valuation is becoming a consideration. With the stock near its recent high and analysts raising targets, some commentary questioned whether much of the favorable news is already reflected in the share price, which could limit near-term upside.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,666,817.72. The trade was a 16.35% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 6,222 shares of company stock valued at $2,540,926 over the last quarter. Company insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the subject of several analyst reports. Royal Bank Of Canada raised their price target on shares of Amgen from $370.00 to $400.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Sanford C. Bernstein increased their price objective on shares of Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. Piper Sandler raised their target price on Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a report on Thursday. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Finally, Canaccord Genuity Group raised their price target on Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $380.43.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.